BioCentury | May 4, 2018
Company News

Accelerator launches Proniras to develop anticonvulsant

...Seattle, Wash. Business: Neurology Sandi Wong tezampanel (LY-293,558) Accelerator Life Science Partners Eli Lilly and Co. Proniras AMPA glutamate receptor (GRIA) (GLUR) Glutamate ionotropic receptor kainate type subunit 1 (GluK1) (GRIK1) (GLUR5)...
BioCentury | May 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

New Therapeutic Targets and Biomarkers: April 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Apr 27, 2018
Company News

Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures. Proniras has received an $89.5 million award from HHS’s Biomedical Advanced Research and Development...
Items per page:
1 - 3 of 3